JP2016523243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523243A5 JP2016523243A5 JP2016520494A JP2016520494A JP2016523243A5 JP 2016523243 A5 JP2016523243 A5 JP 2016523243A5 JP 2016520494 A JP2016520494 A JP 2016520494A JP 2016520494 A JP2016520494 A JP 2016520494A JP 2016523243 A5 JP2016523243 A5 JP 2016523243A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- prevention
- treatment
- chem
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002265 prevention Effects 0.000 claims 54
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 18
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 15
- 208000002705 Glucose Intolerance Diseases 0.000 claims 9
- 102000004877 Insulin Human genes 0.000 claims 9
- 108090001061 Insulin Proteins 0.000 claims 9
- 208000008589 Obesity Diseases 0.000 claims 9
- 230000001154 acute effect Effects 0.000 claims 9
- 229940125396 insulin Drugs 0.000 claims 9
- 235000020824 obesity Nutrition 0.000 claims 9
- 201000009104 prediabetes syndrome Diseases 0.000 claims 9
- 201000006474 Brain Ischemia Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 6
- 208000011231 Crohn disease Diseases 0.000 claims 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 230000000747 cardiac effect Effects 0.000 claims 6
- 206010008118 cerebral infarction Diseases 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 5
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 3
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 3
- 102000007592 Apolipoproteins Human genes 0.000 claims 3
- 108010071619 Apolipoproteins Proteins 0.000 claims 3
- 200000000007 Arterial disease Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000031729 Bacteremia Diseases 0.000 claims 3
- 208000014644 Brain disease Diseases 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 208000028399 Critical Illness Diseases 0.000 claims 3
- 208000014997 Crohn colitis Diseases 0.000 claims 3
- 208000002249 Diabetes Complications Diseases 0.000 claims 3
- 206010012655 Diabetic complications Diseases 0.000 claims 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 3
- 206010013654 Drug abuse Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000007530 Essential hypertension Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010058179 Hypertensive emergency Diseases 0.000 claims 3
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 206010022562 Intermittent claudication Diseases 0.000 claims 3
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 3
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 3
- 208000035180 MODY Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 206010038563 Reocclusion Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 3
- 206010071436 Systolic dysfunction Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 206010046543 Urinary incontinence Diseases 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 3
- 206010001584 alcohol abuse Diseases 0.000 claims 3
- 208000025746 alcohol use disease Diseases 0.000 claims 3
- 239000000164 antipsychotic agent Substances 0.000 claims 3
- 229940005529 antipsychotics Drugs 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000036528 appetite Effects 0.000 claims 3
- 235000019789 appetite Nutrition 0.000 claims 3
- 230000006793 arrhythmia Effects 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000001149 cognitive effect Effects 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 230000003111 delayed effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 201000006549 dyspepsia Diseases 0.000 claims 3
- 230000037406 food intake Effects 0.000 claims 3
- 235000012631 food intake Nutrition 0.000 claims 3
- 230000030135 gastric motility Effects 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000028709 inflammatory response Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 201000005857 malignant hypertension Diseases 0.000 claims 3
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 230000004899 motility Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 208000037891 myocardial injury Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 230000008782 phagocytosis Effects 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 230000033764 rhythmic process Effects 0.000 claims 3
- 230000036186 satiety Effects 0.000 claims 3
- 235000019627 satiety Nutrition 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 230000006641 stabilisation Effects 0.000 claims 3
- 238000011105 stabilization Methods 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 201000009032 substance abuse Diseases 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 206010042772 syncope Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 230000035488 systolic blood pressure Effects 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- WLNMZODBWIWRGN-SSDOTTSWSA-N (2R)-2-amino-2-formyl-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C(=O)[C@](N)(CC1=CNC=N1)C(=O)O WLNMZODBWIWRGN-SSDOTTSWSA-N 0.000 claims 2
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims 2
- ACZFBYCNAVEFLC-YFKPBYRVSA-N (S)-3-(imidazol-5-yl)lactic acid Chemical compound OC(=O)[C@@H](O)CC1=CN=CN1 ACZFBYCNAVEFLC-YFKPBYRVSA-N 0.000 claims 2
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 2
- 229930195721 D-histidine Natural products 0.000 claims 2
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 2
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 229960002885 histidine Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13173068.1 | 2013-06-20 | ||
| EP13173068 | 2013-06-20 | ||
| US201361841995P | 2013-07-02 | 2013-07-02 | |
| US61/841,995 | 2013-07-02 | ||
| EP13175092.9 | 2013-07-04 | ||
| EP13175092 | 2013-07-04 | ||
| US201361845647P | 2013-07-12 | 2013-07-12 | |
| US61/845,647 | 2013-07-12 | ||
| PCT/EP2014/062952 WO2014202727A1 (en) | 2013-06-20 | 2014-06-19 | Glp-1 derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523243A JP2016523243A (ja) | 2016-08-08 |
| JP2016523243A5 true JP2016523243A5 (enExample) | 2017-06-22 |
| JP6475233B2 JP6475233B2 (ja) | 2019-02-27 |
Family
ID=52103985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520494A Active JP6475233B2 (ja) | 2013-06-20 | 2014-06-19 | Ｇｌｐ−１誘導体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10195255B2 (enExample) |
| EP (1) | EP3010546B1 (enExample) |
| JP (1) | JP6475233B2 (enExample) |
| KR (1) | KR20160021183A (enExample) |
| CN (1) | CN105377306B (enExample) |
| AU (1) | AU2014283221A1 (enExample) |
| BR (1) | BR112015030948A2 (enExample) |
| CA (1) | CA2915922A1 (enExample) |
| ES (1) | ES2646538T3 (enExample) |
| MX (1) | MX2015016564A (enExample) |
| WO (1) | WO2014202727A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2646538T3 (es) | 2013-06-20 | 2017-12-14 | Novo Nordisk A/S | Derivados de GLP-1 y sus usos |
| CN106999602B (zh) * | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| US10392428B2 (en) * | 2014-12-17 | 2019-08-27 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| CA2988306A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| LT3393496T (lt) | 2015-12-23 | 2023-12-11 | The Johns Hopkins University | Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija |
| CN106928343A (zh) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 索玛鲁肽的制备方法 |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018113340A1 (zh) * | 2016-12-20 | 2018-06-28 | 中国药科大学 | 多肽p11及其用途 |
| EP4122954B1 (en) | 2018-04-05 | 2024-04-03 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
| US11753455B2 (en) * | 2018-06-21 | 2023-09-12 | Novo Nordisk A/S | Compounds for treatment of obesity |
| CN113226351B (zh) | 2018-10-22 | 2025-01-14 | 詹森药业有限公司 | 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途 |
| CN112912100A (zh) * | 2018-10-26 | 2021-06-04 | 诺和诺德股份有限公司 | 稳定的司美鲁肽组合物及其用途 |
| WO2020118843A1 (zh) * | 2018-12-12 | 2020-06-18 | 四川利通科创生物医药科技有限公司 | 一种glp-1突变体及其制备方法和用途 |
| CN110590934B (zh) * | 2019-09-25 | 2020-12-08 | 北京乐普医药科技有限公司 | 一种glp-1化合物 |
| CN111253475B (zh) * | 2020-02-18 | 2021-03-09 | 江苏诺泰澳赛诺生物制药股份有限公司 | Glp-1激动多肽化合物及其盐与合成方法及用途 |
| AR122579A1 (es) * | 2020-06-12 | 2022-09-21 | Lilly Co Eli | Proceso para preparar un agonista dual glp-1 / glucagón |
| WO2022068920A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| TWI850611B (zh) | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| JP2025512832A (ja) | 2022-03-30 | 2025-04-22 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法 |
| CN117049964A (zh) * | 2023-07-25 | 2023-11-14 | 杭州诺澳生物医药科技有限公司 | 一种脂肪二酸单叔丁酯制备工艺 |
| WO2025185605A1 (en) * | 2024-03-05 | 2025-09-12 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002512175A (ja) | 1998-02-27 | 2002-04-23 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１類似体の誘導体類 |
| EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
| EP1239871A1 (en) | 1999-11-12 | 2002-09-18 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
| GB0020551D0 (en) | 2000-08-22 | 2000-10-11 | Birkett David | Sprinkler system |
| BR0306706A (pt) * | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| JP2006520818A (ja) | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | ポリエチレングリコール結合ｇｌｐ−１化合物 |
| SE525666C2 (sv) * | 2003-07-07 | 2005-03-29 | Atlas Copco Tools Ab | Metod för kvalitetssäkring av skruvförbandsåtdragning |
| EP1670515A2 (en) * | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN101380476A (zh) * | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP5755398B2 (ja) | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー／エス | 伸長されたｇｌｐ−１化合物 |
| BRPI0609676A2 (pt) | 2005-05-13 | 2011-10-18 | Lilly Co Eli | composto de glp-1 peguilado,e, uso do mesmo |
| JP5476304B2 (ja) * | 2007-09-05 | 2014-04-23 | ノボ・ノルデイスク・エー／エス | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 |
| EP2190460B1 (en) | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20120172298A1 (en) | 2009-06-11 | 2012-07-05 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| WO2011073328A1 (en) | 2009-12-16 | 2011-06-23 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| CA2792663A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| WO2012012352A2 (en) | 2010-07-19 | 2012-01-26 | Amidebio, Llc | Modified peptides and proteins |
| WO2012062803A1 (en) | 2010-11-09 | 2012-05-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP2654773B1 (en) * | 2010-12-22 | 2018-10-03 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| EP3225631B1 (en) | 2011-04-12 | 2019-01-09 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| US8541368B2 (en) | 2011-09-23 | 2013-09-24 | Novo Nordisk A/S | Glucagon analogues |
| JP6250034B2 (ja) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| ES2646538T3 (es) | 2013-06-20 | 2017-12-14 | Novo Nordisk A/S | Derivados de GLP-1 y sus usos |
| MX2015016875A (es) | 2013-07-04 | 2016-04-07 | Novo Nordisk As | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| US10392428B2 (en) | 2014-12-17 | 2019-08-27 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
-
2014
- 2014-06-19 ES ES14731951.1T patent/ES2646538T3/es active Active
- 2014-06-19 WO PCT/EP2014/062952 patent/WO2014202727A1/en not_active Ceased
- 2014-06-19 BR BR112015030948A patent/BR112015030948A2/pt not_active Application Discontinuation
- 2014-06-19 CA CA2915922A patent/CA2915922A1/en not_active Withdrawn
- 2014-06-19 MX MX2015016564A patent/MX2015016564A/es unknown
- 2014-06-19 US US14/897,738 patent/US10195255B2/en active Active
- 2014-06-19 EP EP14731951.1A patent/EP3010546B1/en active Active
- 2014-06-19 AU AU2014283221A patent/AU2014283221A1/en not_active Abandoned
- 2014-06-19 CN CN201480035036.1A patent/CN105377306B/zh active Active
- 2014-06-19 JP JP2016520494A patent/JP6475233B2/ja active Active
- 2014-06-19 KR KR1020167000135A patent/KR20160021183A/ko not_active Withdrawn